Head to Head Comparison: Lipocine (LPCN) & Its Rivals
Lipocine (NASDAQ: LPCN) is one of 305 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Lipocine to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, valuation, dividends, earnings and risk.
Risk & Volatility
Lipocine has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Lipocine’s competitors have a beta of 6.54, indicating that their average share price is 554% more volatile than the S&P 500.
This table compares Lipocine and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Lipocine and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Lipocine Competitors||$290.00 million||$35.57 million||166.26|
Lipocine’s competitors have higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and target prices for Lipocine and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Lipocine presently has a consensus target price of $24.67, suggesting a potential upside of 604.76%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.82%. Given Lipocine’s stronger consensus rating and higher possible upside, research analysts clearly believe Lipocine is more favorable than its competitors.
Institutional & Insider Ownership
26.2% of Lipocine shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 11.3% of Lipocine shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Lipocine competitors beat Lipocine on 7 of the 12 factors compared.
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.